肾移植受者移植前与移植后纵向表观基因组范围分析
该研究对154例死亡供肾肾移植受者移植前后的外周血单个核细胞DNA甲基化进行比较,平均随访17年;在FDR校正P≤9×10⁻⁸水平鉴定出5个差异甲基化CpG位点,其中105例无移植后并发症者中693,555个CpG(89.57%)甲基化无显著差异。
要点
- 在FDR校正P≤9×10⁻⁸水平鉴定出5个差异甲基化CpG位点。
- cg23597162(位于JAZF1内)和cg17944885此前与慢性肾脏病相关。
- 105例无移植后并发症者中693,555个CpG(89.57%)甲基化无显著差异。
核心结论
- 在FDR校正P≤9×10⁻⁸水平鉴定出5个差异甲基化CpG位点,包括cg23597162(位于JAZF1内)和cg17944885,二者此前与慢性肾脏病相关。
- 对105例无移植后并发症者的比较显示693,555个CpG(89.57%)甲基化无显著差异(P FDRadj≥0.05),为未来寻找移植后并发症标志物的表观遗传研究提供了重要参考。
研究设计与样本
- 比较同一批肾移植受者移植前与移植后外周血单个核细胞样本的差异甲基化CpG位点,样本量N=154。
- 使用Infinium MethylationEPIC微阵列(Illumina,圣迭戈,加利福尼亚州)检测。
- 受者接受 deceased donor 供肾,平均随访17年。
主要发现
- 5个排名最高的差异甲基化CpG位点在FDR校正P≤9×10⁻⁸水平显著:JAZF1内的cg23597162、BTNL8内的cg25187293、位于ZNF788P与ZNF625-ZNF20之间的cg17944885、位于ASB4与PDK4之间的cg14655917、位于GIMAP6与EIF2AP3之间的cg09839120。
- 无移植后并发症证据的个体(N=105)中,693,555个CpG(89.57%)甲基化无显著差异(P FDRadj≥0.05)。
关键数值与推荐
- 差异甲基化判定标准:FDR校正P≤9×10⁻⁸。
- 无显著差异判定标准:P FDRadj≥0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Kidney transplantation remains the gold standard of treatment for end-stage renal disease (ESRD), with improved patient outcomes compared with dialysis. Epigenome-Wide Association Analysis (EWAS) of DNA methylation may identify markers that contribute to an individual's risk of adverse transplant outcomes, yet only a limited number of EWAS have been conducted in kidney transplant recipients. This EWAS aimed to interrogate the methylation profile of a kidney transplant recipient cohort with minimal posttransplant complications, exploring differences in samples pretransplant and posttransplant. METHODS: We compared differentially methylated cytosine-phosphate-guanine sites (dmCpGs) in samples derived from peripheral blood mononuclear cells of the same kidney transplant recipients, collected both pretransplant and posttransplant (N = 154), using the Infinium MethylationEPIC microarray (Illumina, San Diego, CA). Recipients received kidneys from deceased donors and had a mean of 17 years of follow-up. RESULTS: Five top-ranked dmCpGs were significantly different at false discovery rate (FDR) adjusted P ≤ 9 × 10-8; cg23597162 within JAZF1, cg25187293 within BTNL8, cg17944885, located between ZNF788P and ZNF625-ZNF20, cg14655917 located between ASB4 and PDK4 and cg09839120 located between GIMAP6 and EIF2AP3. CONCLUSION: Five dmCpGs were identified at the generally accepted EWAS critical significance level of FDR adjusted P (P FDRadj) ≤ 9 × 10-8, including cg23597162 (within JAZF1) and cg17944885, which have prior associations with chronic kidney disease (CKD). Comparing individuals with no evidence of posttransplant complications (N = 105) demonstrated that 693,555 CpGs (89.57%) did not display any significant difference in methylation (P FDRadj ≥ 0.05), thereby this study establishes an important reference for future epigenetic studies that seek to identify markers of posttransplant complications.
引用
- Smyth LJ, Kerr KR, Kilner J, et al. Longitudinal Epigenome-Wide Analysis of Kidney Transplant Recipients Pretransplant and Posttransplant. Kidney Int Rep. 2022. PMID: 36815102. doi:10.1016/j.ekir.2022.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。